Outset Medical (NASDAQ:OM) CEO Leslie Trigg Sells 11,794 Shares of Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 11,794 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total transaction of $60,385.28. Following the transaction, the chief executive officer directly owned 107,823 shares of the company’s stock, valued at approximately $552,053.76. This trade represents a 9.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Leslie Trigg also recently made the following trade(s):

• On Wednesday, January 21st, Leslie Trigg sold 2,120 shares of Outset Medical stock. The stock was sold at an average price of $5.05, for a total transaction of $10,706.00.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The shares were sold at an average price of $4.27, for a total transaction of $7,664.65.
• On Monday, November 17th, Leslie Trigg sold 916 shares of Outset Medical stock. The stock was sold at an average price of $4.60, for a total transaction of $4,213.60.

Outset Medical Price Performance

Shares of NASDAQ:OM opened at $5.20 on Thursday. The firm’s 50 day moving average is $4.33 and its two-hundred day moving average is $11.03. The firm has a market capitalization of $94.38 million, a P/E ratio of -0.40 and a beta of 2.07. The company has a current ratio of 7.09, a quick ratio of 5.77 and a debt-to-equity ratio of 0.69. Outset Medical, Inc. has a 52 week low of $3.10 and a 52 week high of $21.98.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. acquired a new position in shares of Outset Medical in the 3rd quarter worth approximately $5,324,000. Geode Capital Management LLC boosted its holdings in Outset Medical by 955.9% during the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after buying an additional 376,196 shares in the last quarter. Pura Vida Investments LLC grew its position in Outset Medical by 8,482.4% in the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after buying an additional 424,120 shares during the last quarter. Ensign Peak Advisors Inc increased its holdings in shares of Outset Medical by 272.4% in the second quarter. Ensign Peak Advisors Inc now owns 314,522 shares of the company’s stock valued at $6,042,000 after buying an additional 230,065 shares in the last quarter. Finally, R Squared Ltd bought a new position in shares of Outset Medical in the third quarter valued at $146,000.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on OM shares. Stifel Nicolaus reduced their price target on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. Wall Street Zen lowered shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. BTIG Research reissued a “buy” rating and set a $17.00 target price on shares of Outset Medical in a research note on Tuesday, December 16th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Outset Medical has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Key Outset Medical News

Here are the key news stories impacting Outset Medical this week:

• Negative Sentiment: CEO Leslie Trigg sold a total of 13,914 shares across Jan. 20–21 (two filings), reducing her stake; the bulk was sold at ~ $5.12 per share. These disclosures can be viewed on the SEC filing. CEO Filings
• Negative Sentiment: General Counsel John L. Brottem sold a total of 10,494 shares across Jan. 20–21 at ~ $5.01–$5.12 per share, cutting his position materially (one filing shows a ~20% reduction). See the SEC disclosure. GC Filings
• Negative Sentiment: EVP Marc Nash sold 6,355 shares across Jan. 20–21 at ~ $4.98–$5.12 per share, reducing his holding by double-digit percentages in one filing. See the SEC filing for details. EVP Filings

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long?term care facilities and emergency response scenarios.